Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamoru Watanabe

Showing results (501-510 of 510) with videos related to

Pageof 51
Sort By:
You have reached the last page of results.This site can display upto 510 results.
Journal of Gastroenterology and Hepatology|October 13, 2017
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: ManagementDong Il Park, Tadakazu Hisamatsu, Minhu Chen, et al.
Journal of Gastroenterology and Hepatology|October 13, 2017
Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessmentDong Ii Park, Tadakazu Hisamatsu, Minhu Chen, et al.
Cellular and Molecular Gastroenterology and Hepatology|December 13, 2025
DOCK10 Regulates Insulin Hypersecretion in Insulinoma and Serves as a Diagnostic and Therapeutic TargetHiromune Katsuda, Go Ito, Franziska Kimmig, et al.
Journal of Crohn'S & Colitis|October 21, 2023
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBDSophie Vieujean, James O Lindsay, Ferdinando D'Amico, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gastroenterology|March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial ResultsJulián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Gastroenterology|August 16, 2016
Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal CancerToshiaki Watanabe, Yoichi Ajioka, Keiichi Mitsuyama, et al.
Journal of Gastroenterology|October 6, 2021
A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in JapanKatsuyoshi Ando, Mikihiro Fujiya, Kenji Watanabe, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 31, 2002
[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer]Toshio Tabei, Masami Ogita, Kouichi Hirata, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionJohan Burisch, Mirabella Zhao, Selwyn Odes, et al.
Pageof 51

Showing results (501-510 of 510) with videos related to

Sort By:
Pageof 51
You have reached the last page of results.This site can display upto 510 results.
Journal of Gastroenterology and Hepatology|October 13, 2017
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: ManagementDong Il Park, Tadakazu Hisamatsu, Minhu Chen, et al.
Journal of Gastroenterology and Hepatology|October 13, 2017
Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessmentDong Ii Park, Tadakazu Hisamatsu, Minhu Chen, et al.
Cellular and Molecular Gastroenterology and Hepatology|December 13, 2025
DOCK10 Regulates Insulin Hypersecretion in Insulinoma and Serves as a Diagnostic and Therapeutic TargetHiromune Katsuda, Go Ito, Franziska Kimmig, et al.
Journal of Crohn'S & Colitis|October 21, 2023
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBDSophie Vieujean, James O Lindsay, Ferdinando D'Amico, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gastroenterology|March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial ResultsJulián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Gastroenterology|August 16, 2016
Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal CancerToshiaki Watanabe, Yoichi Ajioka, Keiichi Mitsuyama, et al.
Journal of Gastroenterology|October 6, 2021
A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in JapanKatsuyoshi Ando, Mikihiro Fujiya, Kenji Watanabe, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 31, 2002
[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer]Toshio Tabei, Masami Ogita, Kouichi Hirata, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionJohan Burisch, Mirabella Zhao, Selwyn Odes, et al.
Pageof 51